A phase 1b study for VEN/GILT enrolled patients with FLT3-wild-type or FLT3-mutant (dose escalation) and FLT3-mutant (dose expansion) R/R AML [135]. The gene discussed is FLT3; the disease is acute myeloid leukemia.